PSMA-PET research: addressing challenges and prospects – Authors' reply

[...]cancer registry data do not consistently record cancer-specific survival outcomes or quality of life measures. In our study, image acquisition followed in-house protocols that were in line with current international guideline recommendations3 Additionally, the same PET radioligand was used in nearly all patients (1557 [97%] of 1612 patients had scans done by [68Ga]-PSMA-11). [...]minor variations in imaging protocols are not expected to introduce significant bias. BAH reports consulting fees from Lightpoint Medical, Janssen, Bayer, ABX, Astellas, Merck, Amgen, MSD/Pfizer, Novartis, Bristol Myers Squibb (BMS), Onkowissen, POINT Biopharma, Ipsen, AstraZeneca, Lightpoint medical, Telix and Accord Healthcare; travel support from AstraZeneca, BMS, Janssen, Bayer, and Ipsen; grants or contracts from Janssen, DFG, Novartis, and BMS; royalties or licenses from Uromed; payment or honoraria from Janssen, Amgen, Astellas, and Monrol; participation on a data safety monitoring board or advisory board for Janssen, and ABX; and a leadership role for Deutsche Gesellschaft für Urologie.